The Investment Column: Cash-rich Amec is keen to engineer acquisitions

Galliford Try; Phytopharm


Our view: Buy

Share price: 849.5p (+23p)

According to the engineering group Amec's chief executive, Samir Brikho, there is absolutely nothing to worry about. Indeed, he is so confident about the company's future that he does not see any risk for the next six or seven years.

Amec issued a trading statement yesterday saying that 2008 Ebitda margin expectations had edged up to 6.5 per cent from 6 per cent. Net cash will exceed £600m, which will enable the group to "make selective acquisitions".

The stock has performed well since dipping as low as 642p in January, but the analysts reckon there is plenty more to come. Those at Merrill Lynch say that trading at 8.3 times EV/Ebitda, Amec operates at an 11 per cent discount to UK-based oil services companies. The analysts reckon the shares are on their way to 1030p, and investors should buy now. They largely agree with Mr Brikho's risk assessment, saying, "there is currently a wide gap between the industry's cash generation [$65 to $140 a barrel] and investment basis [$40 to $60 a barrel], it would take a dramatic fall in oil prices, in our view, to see industry spending patterns change significantly".

The company itself does not like commenting on the share price, however it does get a bit hot under the collar about a note from Seymour Pierce, dismissing it as uninformed. The analysts say that while the company has done well in recent years, that performance is already priced into the stock and the shares do not have any capacity left.

There are not many sectors that are performing like oil. As other markets suffer, so more buyers will be attracted to the black stuff and companies that operate in the oil market. There is more room for growth. Buy.

Galliford Try

Our view: Cautious hold

Share price: 32.5p(+4.75p)

Yes, ok, Galliford Try is a builder, but before readers move straight down to the next piece assuming that anything connected with building is toxic, investors will be interested to learn that the group's stock leapt 14.6 per cent by yesterday's close. The shares spiked after an upbeat trading statement, which said that full-year profits will be in line with forecasts, at no less than £60m.

The obvious point to note is that this is in stark contrast to the rest of the sector. The press is full of premature obituaries for the likes of Taylor Wimpey and Barratt Development. However, this presents an opportunity for investors, say watchers at Numis. They agree that the sector is "terminally ill" but management's strategy of running the company for cash is "proving successful".

Despite Numis ascribing no value to the housebuilding operation, they say that, "putting zero value on housing, construction on 8 times and affordable housing on 10 times (in line with our concerns that new build here could be vulnerable) gets us to 60p, still 82 per cent above the current share price".

All fair enough, but before investors get too carried away, remember the building sector is close to imploding, and even Galliford's chief executive, Greg Fitzgerald, says that things are getting tougher in house building, but points out that the market misses the fact that the company is a much bigger contractor. There will be no increase in dividend, and margins will be hit by the market.

Experts at Merrill Lynch go further, arguing thatpre-tax profit this year will be £60m, resulting in earnings per share of 11.1p, changing to £39m and 7.4p next year respectively. Cautious hold.

Phytopharm

Our view: Hold

Share price: 20.25p (-0.25p)

There is a plethora of small drugs companies spending lots of money developing what they hope will be the next blockbuster cure for a nasty disease. The problem is that often they raise money to put the treatment through the first few trials and then run out towards the end of the process.

That is why analysts at KBC say Phytopharm, which issued a positive trading statement yesterday, is different. The group makes an appetite suppressant, Hoodia, which is due to be used in Unilever's Slim Fast dieting products; the group hopes that this will fund research for its other treatments for the likes of Parkinson's.

UK biotech groups do not have a history of doing well for shareholders. Some do eventually come good, usually by being bought by one of the pharma giants. The only companies that ever do well have plenty of cash. With its Unilever tie-up, Phytopharm hopes to join those ranks. KBC says Hoodia has a 50 per cent chance of phase three trial success, which has already been funded. Hold.

Start your day with The Independent, sign up for daily news emails
PROMOTED VIDEO
News
ebooksNow available in paperback
Sport
Scunthorpe goalkeeper Sam Slocombe (left) is congratulated by winning penalty taker Miguel Llera (right)
football
Life and Style
A woman walks by a pandal art installation entitled 'Mars Mission' with the figure of an astronaut during the Durga Puja festival in Calcutta, India
techHow we’ll investigate the existence of, and maybe move in with, our alien neighbours
Arts and Entertainment
Sir Ian McKellen tempts the Cookie Monster
tvSir Ian McKellen joins the Cookie Monster for a lesson on temptation
News
i100
Travel
Tourists bask in the sun beneath the skyscrapers of Dubai
travelBritish embassy uses social media campaign to issue travel advice for festive holiday-makers in UAE
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Ashdown Group: Marketing Services Manager - (communications, testing, DM)

£32000 - £35000 per annum + benefits: Ashdown Group: Marketing Services Manage...

Guru Careers: Finance Account Manager

£Neg. (DOE) + Excellent Benefits: Guru Careers: A Finance Account Manager with...

Ashdown Group: Java Developer - Hertfordshire - £47,000 + bonus + benefits

£40000 - £470000 per annum + bonus: Ashdown Group: Java Developer / J2EE Devel...

Ashdown Group: Direct Marketing Manager - B2C, Financial Services - Slough

£45000 - £55000 per annum + Benefits: Ashdown Group: An exciting opportunity h...

Day In a Page

Jeb Bush vs Hillary Clinton: The power dynamics of the two first families

Jeb Bush vs Hillary Clinton

Karen Tumulty explores the power dynamics of the two first families
Stockholm is rivalling Silicon Valley with a hotbed of technology start-ups

Stockholm is rivalling Silicon Valley

The Swedish capital is home to two of the most popular video games in the world, as well as thousands of technology start-ups worth hundreds of millions of pounds – and it's all happened since 2009
Did Japanese workers really get their symbols mixed up and display Santa on a crucifix?

Crucified Santa: Urban myth refuses to die

The story goes that Japanese store workers created a life-size effigy of a smiling "Father Kurisumasu" attached to a facsimile of Our Lord's final instrument of torture
Jennifer Saunders and Kate Moss join David Walliams on set for TV adaptation of The Boy in the Dress

The Boy in the Dress: On set with the stars

Walliams' story about a boy who goes to school in a dress will be shown this Christmas
La Famille Bélier is being touted as this year's Amelie - so why are many in the deaf community outraged by it?

Deaf community outraged by La Famille Bélier

The new film tells the story of a deaf-mute farming family and is being touted as this year's Amelie
10 best high-end laptops

10 best high-end laptops

From lightweight and zippy devices to gaming beasts, we test the latest in top-spec portable computers
Michael Carberry: ‘After such a tough time, I’m not sure I will stay in the game’

Michael Carberry: ‘After such a tough time, I’m not sure I will stay in the game’

The batsman has grown disillusioned after England’s Ashes debacle and allegations linking him to the Pietersen affair
Susie Wolff: A driving force in battle for equality behind the wheel

Susie Wolff: A driving force in battle for equality behind the wheel

The Williams driver has had plenty of doubters, but hopes she will be judged by her ability in the cockpit
Adam Gemili interview: 'No abs Adam' plans to muscle in on Usain Bolt's turf

'No abs Adam' plans to muscle in on Usain Bolt's turf

After a year touched by tragedy, Adam Gemili wants to become the sixth Briton to run a sub-10sec 100m
Calls for a military mental health 'quality mark'

Homeless Veterans campaign

Expert calls for military mental health 'quality mark'
Racton Man: Analysis shows famous skeleton was a 6ft Bronze Age superman

Meet Racton Man

Analysis shows famous skeleton was a 6ft Bronze Age superman
Garden Bridge: St Paul’s adds to £175m project’s troubled waters

Garden Bridge

St Paul’s adds to £175m project’s troubled waters
Stuff your own Christmas mouse ornament: An evening class in taxidermy with a festive feel

Stuff your own Christmas mouse ornament

An evening class in taxidermy with a festive feel
Joint Enterprise: The legal doctrine which critics say has caused hundreds of miscarriages of justice

Joint Enterprise

The legal doctrine which critics say has caused hundreds of miscarriages of justice
Freud and Eros: Love, Lust and Longing at the Freud Museum: Objects of Desire

Freud and Eros

Love, Lust and Longing at the Freud Museum